Screener
AbbVie ABBV Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $16.99B+10.2% | $15B+12.4% | $16.62B+10.0% | $15.78B+9.1% | $15.42B+6.6% | ||
| $4.29B-1.3% | $4.22B+5.4% | $4.55B+3.5% | $5.3B+25.9% | $4.35B+3.4% | ||
| $12.7B+14.6% | $10.78B+15.4% | $12.07B+12.7% | $10.47B+2.2% | $11.08B+8.0% | ||
| 74.7%+2.9pp | 71.9%+1.9pp | 72.6%+1.7pp | 66.4%-4.5pp | 71.8%+0.9pp | ||
| $3.63B+11.7% | $3.58B+8.7% | $3.9B+1.0% | $3.57B-15.1% | $3.25B-3.7% | ||
| $10.56B+0.3% | $11.01B+14.6% | $12.07B-27.2% | $13.87B+30.5% | $10.53B+0.6% | ||
| $6.43B+31.4% | $3.99B+6.9% | $4.54B— | $1.9B-50.3% | $4.89B+22.4% | ||
| 37.9%+6.1pp | 26.6%-1.4pp | 27.3%— | 12.1%-14.4pp | 31.7%+4.1pp | ||
| $4.28B+175% | $1.04B-37.4% | $2.67B— | $714M-65.7% | $1.55B-27.6% | ||
| $662M+8.0% | $342M-8.1% | $853M+138% | $526M+1.2% | $613M-20.7% | ||
| $3.61B+285% | $695M-46.0% | $1.82B+8,355% | $186M-88.1% | $938M-31.5% | ||
| 21.3%+15.2pp | 4.6%-5.0pp | 10.9%+11.1pp | 1.2%-9.6pp | 6.1%-3.4pp | ||
| $2.03+290% | $0.39-45.8% | $1.02+5,200% | $0.10-88.6% | $0.52-32.5% | ||
| $6.43B+31.4% | $3.99B+6.9% | $4.54B— | $1.9B-50.3% | $4.89B+22.4% |
FAQ
- What is AbbVie's revenue?
- AbbVie (ABBV) generated $64.4B in revenue over the trailing twelve months, up 10.4% year over year.
- Is AbbVie profitable?
- AbbVie reported $6.3B in net income over the trailing twelve months, a 9.8% net margin.
- What are AbbVie's profit margins?
- Gross margin is 71.5% and operating margin is 26.2%, with a 9.8% net margin.
- What is AbbVie's earnings per share?
- AbbVie's diluted EPS over the trailing twelve months is $3.54.
- Where does AbbVie's income statement data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
